Improved long-term survival in patients on combination therapies following an incident acute myocardial infarction: A longitudinal population-based study

Heart

Volumn 99, Issue 18, 2013, Pages 1353-1358

  Gunnell, Anthony S ^a   Einarsdóttir, Kristjana ^b   Sanfilippo, Frank ^c   Liew, Danny ^d   Holman, C D'arcy J ^c   Briffa, Tom ^c  

^a EDITH COWAN UNIVERSITY   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CANDESARTAN; CAPTOPRIL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPROSARTAN; FLUINDOSTATIN; FOSINOPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; LISINOPRIL; METOPROLOL; OXPRENOLOL; PERINDOPRIL; PINDOLOL; PRAVASTATIN; QUINAPRIL; RAMIPRIL; SIMVASTATIN; TELMISARTAN; TRANDOLAPRIL;

AGED; ARTICLE; AUSTRALIA; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE REGISTRY; FEMALE; HEART INFARCTION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; INCIDENCE; LONG TERM SURVIVAL; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; SECONDARY PREVENTION; SEX DIFFERENCE;

ACUTE MYOCARDIAL INFARCTION; EPIDEMIOLOGY; MEDICATIONS; MORTALITY; SEX;

ADRENERGIC BETA-ANTAGONISTS; AGED; AGED, 80 AND OVER; CAUSE OF DEATH; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MYOCARDIAL INFARCTION; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; WESTERN AUSTRALIA;

EID: 84882646601     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2013-304348     Document Type: Article

References (30)

1. Mendis SPP, Norrving B, ed. Global atlas on cardiovascular disease prevention and control. Geneva: World Health Organization, 2011.
2. AIHW. Cardiovascular disease: Australian facts 2011. Canberra: Australian Institute of Health and Welfare, 2011.
3. Cooper A, Skinner J, Nherera L, et al. Clinical guidelines and evidence review for post myocardial infarction: secondary prevention in primary and secondary care for patients following a myocardial infarction. London: National Collaborating Centre for Primary Care and Royal College of General Practitioners., 2007.
4. Acute Coronary Syndrome Guidelines Working Group. Guidelines for the management of acute coronary syndromes 2006. Med J Aust 2006;184:S1-32.
5. Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med 2007;356:2388-98.
6. Bangalore S, Steg G, Deedwania P, et al. beta-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA 2012;308:1340-9.
7. Bata IR, Gregor RD, Wolf HK, et al. Trends in five-year survival of patients discharged after acute myocardial infarction. Can J Cardiol 2006;22:399-404.
8. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338:b1665.
9. Lonn E, Bosch J, Teo KK, et al. The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions. Circulation 2010;122:2078-88.
10. Zeymer U, Junger C, Zahn R, et al. Effects of a secondary prevention combination therapy with an aspirin, an ACE inhibitor and a statin on 1-year mortality of patients with acute myocardial infarction treated with a beta-blocker. Support for a polypill approach. Curr Med Res Opin 2011;27:1563-70.
11. Holman CD, Bass AJ, Rouse IL, et al. Population-based linkage of health records in Western Australia: development of a health services research linked database. Aust N Z J Public Health 1999;23:453-9.
12. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol 1993;46:1075-9; discussion 81-90.
13. Shekelle PG, Rich MW, Morton SC, et al. Efficacy of angiotensin- converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 2003;41:1529-38.
14. Kappert K, Bohm M, Schmieder R, et al. Impact of sex on cardiovascular outcome in patients at high cardiovascular risk: analysis of the Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects With Cardiovascular Disease (TRANSCEND) and the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET). Circulation 2012;126:934-41.
15. Fleg JL, Aronow WS, Frishman WH. Cardiovascular drug therapy in the elderly: benefits and challenges. Nat Rev Cardiol 2011;8:13-28.
16. Norman PE, Semmens JB, Lawrence-Brown MM, et al. Long term relative survival after surgery for abdominal aortic aneurysm in western Australia: population based study. BMJ 1998;317:852-6.
17. ABS (Australian Bureau of Statistics). Household Expenditure on Health: A Snapshot, 2004-05. Cat no. 4836.0.55.001. Canberra, 2008.
18. Dagenais GR, Pogue J, Fox K, et al. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 2006;368:581-8.
19. Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004;351:2058-68.
20. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease. J Hum Hypertens 2004;18:781-8.
21. Bramlage P, Messer C, Bitterlich N, et al. The effect of optimal medical therapy on 1-year mortality after acute myocardial infarction. Heart 2010;96:604-9.
22. Danchin N, Cambou JP, Hanania G, et al. Impact of combined secondary prevention therapy after myocardial infarction: data from a nationwide French registry. Am Heart J 2005;150:1147-53.
23. Carey KM, Comee MR, Donovan JL, et al. A polypill for all? Critical review of the polypill literature for primary prevention of cardiovascular disease and stroke. Ann Pharmacother 2012;46:688-95.
24. Yan AT, Yan RT, Tan M, et al. Optimal medical therapy at discharge in patients with acute coronary syndromes: temporal changes, characteristics, and 1-year outcome. Am Heart J 2007;154:1108-15.
25. He YM, Yang XJ, Zhao X, et al. beta-Blockers in heart failure: benefits of beta-blockers according to varying male proportions of study patients. Clin Cardiol 2012;35:505-11.
26. Lee PY, Alexander KP, Hammill BG, et al. Representation of elderly persons and women in published randomized trials of acute coronary syndromes. JAMA 2001;286:708-13.
27. Mega JL, Morrow DA, Ostor E, et al. Outcomes and optimal antithrombotic therapy in women undergoing fibrinolysis for ST-elevation myocardial infarction. Circulation 2007;115:2822-8.
28. Dey S, Flather MD, Devlin G, et al. Sex-related differences in the presentation, treatment and outcomes among patients with acute coronary syndromes: the Global Registry of Acute Coronary Events. Heart 2009;95:20-6.
29. Hardoon SL, Whincup PH, Petersen I, et al. Trends in longer-term survival following an acute myocardial infarction and prescribing of evidenced-based medications in primary care in the UK from 1991: a longitudinal population-based study. J Epidemiol Community Health 2011;65:770-4.
30. Hansen KW, Hvelplund A, Abildstrom SZ, et al. No gender differences in prognosis and preventive treatment in patients with AMI without significant stenoses. Eur J Prev Cardiol 2012;19:746-54.